HOME >> MEDICINE >> NEWS
Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA

Washington, DC, October 20, 2004 Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced today that ADDERALL XR (an extended release, mixed salts amphetamine product) is effective and generally well-tolerated for adolescents with attention-deficit/hyperactivity disorder (ADHD). The short- and long-term study results of the multicenter Phase 3 study were presented today in Washington, DC.

"To date, well-designed, controlled studies of ADHD medications in adolescents have been extremely rare," said lead investigator Stephen Grcevich, M.D., Case Western Reserve University School of Medicine and President and Founder of The Family Center by the Falls, in Chagrin Falls, Ohio. "While the vast majority of safety and efficacy studies with ADHD medications have been conducted in school age children, and more recently, in adult populations, physicians are being asked with increasing frequency to treat adolescents with significant functional impairment associated with ADHD. For this reason, it is critically important to access this long-term data to guide physicians in our treatment of this specific population group."

ADHD is considered the most commonly diagnosed psychiatric disorder in children and adolescents, and affects approximately three to seven percent of all school-age children, or approximately two million children in the U.S. Results from follow-up studies of subjects with ADHD published over the past two decades suggest that up to 80 percent of children diagnosed with ADHD will continue to exhibit symptoms in adolescence and up to 65 percent in adulthood.-

The three main symptoms of ADHD include inattention, hyperactivity and impulsivity. If left untreated, these symptoms may seriously and adversely affect patients as well as their families and friends. Findings from a national survey, "Capturing America's Attention," released earlier this year found that adults with ADHD tend to report lower educ
'"/>

Contact: Marion E. Glick
917-301-4206
Porter Novelli
20-Oct-2004


Page: 1 2 3

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
6. Long-term use of antibiotics possibly linked with increased risk of breast cancer
7. Long-term follow-up of mortality in patients with community-acquired pneumonia
8. Long-term outcome of epilepsy surgery is favorable for many
9. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
10. Long-term avoidance of milk in children results in poor bone health
11. Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since 2004, the ... 26th as Mesothelioma Awareness Day . On this day, and in the weeks ... of becoming involved and helping the cause. , “One of the ways a person ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, a leading global provider ... solutions will demonstrate multiple prototypes from its Innovation Lab during its 8th Annual ... the only European event dedicated to providing case studies and pragmatic information on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... certifies products for the water, food, health sciences and consumer goods industries, has ... for their advanced iron filtration media, Pro-OX Manganese Dioxide. , Developed by a ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
Cached News: